Genexine’s GX-BP1 (SOX2 bioPROTAC) Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination
Genexine, Inc. (KOSDAQ: 095700) announced that Jaehyun Choi, Ph.D., CEO and Head of R&D, presented new preclinical data for GX-BP1, the company’s SOX2-targeting bioPROTAC, at the 2026 World Conference on Lung Cancer (WCLC) in Seoul on September 13.The mini oral presentation, titled ‘Lung-Targeted m…